Novelix Pharmaceuticals Limited
BSE: NOVELIX · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Novelix Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Novelix Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
P/E
47.6x
Q4 FY26 · standalone
EV/EBITDA
56.9x
Q4 FY26 · standalone
NET PROFIT MARGIN
3.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Novelix Pharmaceuticals LimitedNOVELIX | ₹198 Cr | 47.62 | 56.89 | — | 2.6% | 10.3% | 13.2% | +76.4% |
Indegene Ltd.INDGN | ₹14,419 Cr | 35.52 | 19.70 | 30.4% | 18.8% | 13.9% | 17.4% | +4.9% |
Suven Life Sciences LimitedSUVEN | ₹9,659 Cr | -20.71 | -27.94 | 17.3% | -557.4% | -100.5% | -99.8% | +48.9% |
Vimta LabsVIMTALABS | ₹2,728 Cr | 32.72 | 17.34 | 15.2% | 37.3% | 19.1% | 24.1% | -18.3% |
Fabtech Technologies LimitedFABTECH | ₹661 Cr | 10.28 | 9.04 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹235 Cr | 14.71 | 37.62 | — | 7.4% | 49.8% | 24.2% | +4.9% |
As of Q4 FY26
Financials
Novelix Pharmaceuticals Limited
BSE: NOVELIX · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Novelix Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Novelix Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
P/E
47.6x
Q4 FY26 · standalone
EV/EBITDA
56.9x
Q4 FY26 · standalone
NET PROFIT MARGIN
3.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Healthcare Research, Analytics & Technology
As of Q4 FY26